(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/215809 A2

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/US2024/023942

(22) International Filing Date:
10 April 2024 (10.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/495,543 11 April 2023 (11.04.2023) US

(71) Applicant: **COGENT BIOSCIENCES, INC.** [US/US]; 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451 (US).


(72) Inventors: **SALITURO, Leah J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FULTON, Jennifer**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **JALLURI, Ravi Kumar**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **VINE, Logan E.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **BETTENDORF, Tanna**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FISCHER, John**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FELL, Jay B.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **CHICARELLI, Mark J.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **CHATTERJEE, Payal**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **MALINKY, Cori A.**; c/o Cogent Biosciences, Inc., 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US).

(74) Agent: **SIEKMAN, Michael T.** et al.; GOODWIN PROCTER LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ERBB2 INHIBITORS



(I)

(57) Abstract: A compound having the following structure of Formula (I): (I) or a stereoisomer of the compound, pharmaceutically acceptable salt, or tautomer thereof, wherein E, L, R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{5b}, R^{8}, Y^{1}, Y^{2}, Y^{3}, Y^{4}, Y^{5}, Y^{6}, X^{1}, X^{2}, Z^{1}, and Z^{2} are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

WO 2024/215809 A2

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*